Development and Validation of HPLC-UV Method for the Determination of Favipiravir in Human Plasma

Development and Validation of HPLC-UV Method for the Determination of Favipiravir in Human Plasma

Introduction. Coronavirus disease (COVID-19) is an acute infectious disease caused by SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2). Favipiravir is a synthetic prodrug with antiviral activity used for the treatment of COVID-19. There are oral and parenteral dosage forms of fav...

Full description

Saved in:
Bibliographic Details
Main Authors: T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2022-09-01
Series:Разработка и регистрация лекарственных средств
Subjects:
favipiravir
covid-19
plasma
hplc-uv
validation
pharmacokinetics
Online Access:https://www.pharmjournal.ru/jour/article/view/1304
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmjournal.ru/jour/article/view/1304

Similar Items